Cargando…

Management of venous thromboembolism in patients with cancer: role of dalteparin

Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years...

Descripción completa

Detalles Bibliográficos
Autor principal: Linkins, Lori-Ann
Formato: Texto
Lenguaje:English
Publicado: Dove Medical Press 2008
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496976/
https://www.ncbi.nlm.nih.gov/pubmed/18561503
_version_ 1782158277102010368
author Linkins, Lori-Ann
author_facet Linkins, Lori-Ann
author_sort Linkins, Lori-Ann
collection PubMed
description Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer.
format Text
id pubmed-2496976
institution National Center for Biotechnology Information
language English
publishDate 2008
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-24969762008-08-26 Management of venous thromboembolism in patients with cancer: role of dalteparin Linkins, Lori-Ann Vasc Health Risk Manag Review Cancer is a major risk factor for the development of venous thromboembolism (VTE). Conventional anticoagulant therapy with a vitamin K antagonist is more problematic in cancer patients due to an increased risk of recurrent VTE, and an increased risk of anticoagulant-related bleeding. In recent years, there has been a shift toward treating cancer patients with VTE with extended duration dalteparin. Dalteparin, a low-molecular-weight heparin, has been shown to be more effective, and as safe as conventional anticoagulant therapy, in cancer patients with VTE. This paper will (a) review the relationship between cancer and VTE, and (b) provide an overview of the role of dalteparin in the management of VTE in patients with cancer. Dove Medical Press 2008-04 2008-04 /pmc/articles/PMC2496976/ /pubmed/18561503 Text en © 2008 Dove Medical Press Limited. All rights reserved
spellingShingle Review
Linkins, Lori-Ann
Management of venous thromboembolism in patients with cancer: role of dalteparin
title Management of venous thromboembolism in patients with cancer: role of dalteparin
title_full Management of venous thromboembolism in patients with cancer: role of dalteparin
title_fullStr Management of venous thromboembolism in patients with cancer: role of dalteparin
title_full_unstemmed Management of venous thromboembolism in patients with cancer: role of dalteparin
title_short Management of venous thromboembolism in patients with cancer: role of dalteparin
title_sort management of venous thromboembolism in patients with cancer: role of dalteparin
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2496976/
https://www.ncbi.nlm.nih.gov/pubmed/18561503
work_keys_str_mv AT linkinsloriann managementofvenousthromboembolisminpatientswithcancerroleofdalteparin